Dose-Escalation and Dose-Expansion Study of ZX-4081 in Patients With Advanced Solid Tumors
Status:
Not yet recruiting
Trial end date:
2024-05-01
Target enrollment:
Participant gender:
Summary
A Phase 1, first-in-human, open-label, multicenter, dose escalation and dose expansion study
to investigate the safety, tolerability, PK, pharmacodynamics, and preliminary antitumor
activity of ZX-4081 administered orally (PO) twice daily (BID) in 28-day cycles in patients
with Advanced Solid Tumors.